Business Context and Reporting Period
Company: Henry Schein, Inc. (HSIC)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 28, 2024 (52 weeks)
Business Overview: Henry Schein is the world's largest provider of health care products and services to office-based dental and medical practitioners. The company operates through three revised reportable segments: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It serves over one million customers in 33 countries and territories.
Key Financial Metrics
| Metric | 2024 (in millions) | 2023 (in millions) |
|---|---|---|
| Net Sales | $12,673 | $12,339 |
| Gross Profit | $4,016 | $3,860 |
| Gross Margin | 31.7% | 31.3% |
| Operating Income | $621 | $615 |
| Net Income (Attributable to HSIC) | $390 | $416 |
| Diluted EPS | $3.05 | $3.16 |
| Operating Cash Flow | $848 | $500 |
| Total Debt | $2,536 | $2,351 |
| Cash and Cash Equivalents | $122 | $171 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 2.7% to $12.67 billion. Growth was driven by acquisitions (3.3% contribution) and foreign exchange, partially offset by a 0.4% decline in local currency internal sales due to lower PPE/COVID test kit sales and migration to lower-priced products.
- Profitability: Operating income increased slightly to $621 million, while Net Income attributable to Henry Schein, Inc. decreased 6.3% to $390 million. The effective tax rate increased to 24.9% from 22.1%.
- Restructuring: The company recorded $110 million in restructuring and integration costs in 2024, up from $80 million in 2023. This includes a new "2024 Plan" initiated in August 2024 to integrate acquisitions and right-size operations, resulting in $73 million in charges.
- Cyber Incident Impact: The October 2023 cyber incident continued to impact 2024 results. The company incurred $9 million in direct expenses and received $40 million in insurance proceeds (with $20 million of the claim still under review). Sales decreases in dental and medical distribution were attributed to lower sales to episodic customers following the incident.
- Segment Revision: In Q4 2024, the company revised its reportable segments to align with management structure. Prior period data has been recast.
Guidance, Outlook, and Risks
- Strategic Partnership: On January 29, 2025, Henry Schein announced a strategic partnership with KKR & Co. Inc. KKR will invest an additional $250 million for a 12% stake (with an option to increase to 14.9%) and will appoint two representatives to the Board of Directors.
- Share Repurchases: The company plans to accelerate share repurchases. As of December 28, 2024, $380 million remained available under the existing program. On January 27, 2025, the Board authorized an additional $500 million for repurchases.
- Key Risks:
- Cybersecurity: Ongoing risks related to the October 2023 incident and potential future attacks on information systems.
- Regulatory: Extensive exposure to healthcare regulations (FDA, DEA, DSCSA, EU MDR) and potential changes in reimbursement rates and drug pricing laws (e.g., Inflation Reduction Act).
- Supply Chain: Dependence on third-party suppliers for raw materials and products; recent shortages and cost increases have impacted margins.
- Macroeconomic: Inflationary pressures, interest rate fluctuations, and geopolitical instability.
Investor Verification Checklist
- KKR Partnership Terms: Verify the final closing conditions and the specific voting rights associated with the new KKR board seats.
- Cyber Incident Resolution: Monitor the status of the remaining $20 million insurance claim and any potential class action litigation settlements (a $2.9 million settlement was approved in February 2025).
- Restructuring Execution: Track the execution of the 2024 Restructuring Plan and the associated future cash outflows for severance and exit costs.
- Segment Performance: Analyze the performance of the newly defined segments, specifically the growth trajectory of Global Specialty Products and Global Technology versus the core Distribution business.
- Debt Maturity Profile: Review the upcoming debt maturities, including the $750 million term loan maturing in July 2026 and the impact of rising interest rates on variable rate debt.